Similar articles

• Lenalidomide for bortezomib-resistant multiple myeloma.

  Briani C, Berno T, Campagnolo M, Zambello R. Briani C, et al. Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c1. Nat Rev Clin Oncol. 2010. PMID: 20824906 No abstract available.
• Drugs: More shots on target.

  Appel A. Appel A. Nature. 2011 Dec 14;480(7377):S40-2. doi: 10.1038/480S40a. Nature. 2011. PMID: 22169800 No abstract available.
• Multiple myeloma.

  Kyle RA, Rajkumar SV. Kyle RA, et al. N Engl J Med. 2004 Oct 28;351(18):1860-73. doi: 10.1056/NEJMra041875. N Engl J Med. 2004. PMID: 15509819 Review. No abstract available.
• Diagnosis and the current trends in multiple myeloma therapy.

  Dmoszyńska A. Dmoszyńska A. Pol Arch Med Wewn. 2008 Oct;118(10):563-6. Pol Arch Med Wewn. 2008. PMID: 19112817 Review.
• Clinical update: novel targets in multiple myeloma.

  Anderson KC. Anderson KC. Semin Oncol. 2004 Dec;31(6 Suppl 16):27-32; discussion 33. doi: 10.1053/j.seminoncol.2004.10.016. Semin Oncol. 2004. PMID: 15799242 Review.